Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
about
Targeted radionuclide therapies for pancreatic cancerManagement of patients with hepatic metastases from neuroendocrine tumorsPhase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceSubacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volumeA novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETsTherapeutic strategies for neuroendocrine liver metastases.[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression.Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms.Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths
P2860
Q26801364-2F3335A3-21CC-4DE9-8BF5-0DF87D0A0E57Q27008832-EC38AF95-A533-42B3-8B4D-42476B22500CQ33438326-0765B68E-F27B-4683-A3FA-368A8EE783F0Q33700134-ADF02F16-40F6-4AE6-ADAC-5B55F94CECB9Q35244181-5ECACEEF-E32A-41A7-9B6E-E3C8FE38F0EAQ35917106-BFC98FAD-0AF0-4F58-B2C6-983FD38F53B1Q36516035-7B2F8E9A-8524-4D06-B2BA-A75F19C7B300Q37156083-DD137DD0-72AC-458B-A23B-351A3B5437BDQ37273187-CEF0A2C0-8D94-41D0-BD13-4F6C1EF999D1Q38241463-102E9C08-DC4E-45D0-9195-4733482AD55CQ38255979-2113F5D5-B130-46D6-A895-D9F4A4B8697CQ38694105-C13917A4-19F7-4347-A5E9-8805A3D8F38CQ38909078-B49B8ECC-2B76-489C-BB56-C4D966D3D54BQ38936576-C81E31D8-1100-42B4-BBC9-DF437DF6976AQ41161125-C5DFA0D4-601B-4B95-8A90-4A02255F6CCCQ42345704-3774D040-EE9A-48AB-8E69-1E3BCF18F0C4Q47097042-E42401D2-060E-4F5C-B31E-15BB7B8F1D2EQ47589004-666AD062-60BF-4C7D-AEC6-4718583766FDQ47653267-AB0E6D92-3667-44A4-97E4-E808A0AFF0B3Q49451226-A679F056-D7A1-4846-851C-A67C5B2075B9Q52571250-4361F953-C04E-4A54-8201-54CE9A288112Q52964782-59D785D4-E234-4FCE-8196-E13DA4F75CC9Q56962802-357E15DA-D2FB-4E37-A4DD-EBD7BB411AA3
P2860
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@ast
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@en
type
label
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@ast
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@en
prefLabel
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@ast
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@en
P2093
P1476
Long-term hematotoxicity after ...... therapy with 177Lu-octreotate.
@en
P2093
Amir Sabet
Hans-Jürgen Biersack
Karin Mayer
Khaled Ezziddin
Samer Ezziddin
Stefan Guhlke
Thorsten Pöppel
Ulrich-Frank Pape
P304
P356
10.2967/JNUMED.112.119347
P407
P577
2013-09-05T00:00:00Z